Summary

The global compounding pharmacy market is projected to reach USD 21.01 billion by 2031 from USD 15.48 billion in 2026, reflecting a CAGR of 6.3% over the forecast period. The global compounding pharmacy market is projected to expand significantly over the forecast period, driven by rising demand for personalized medications, customized dosage forms, and formulations not commercially available. Market growth is supported by the increasing prevalence of chronic and complex conditions, greater adoption of patient-specific therapies, and growing reliance on compounded medications during drug shortages. Advances in automated compounding systems, digital prescription management, and precision dosing technologies are further improving efficiency and quality. However, stringent regulatory requirements, high investments in sterile compounding facilities, specialized workforce requirements, and quality-control challenges may constrain market expansion, particularly for smaller compounding pharmacies.

By product type, oral drugs held the largest share of the compounding pharmacy market in 2025.

By product type, the compounding pharmacy market is segmented into topical drugs, oral drugs, parenteral drugs, rectal drugs, nasal drugs, ophthalmic drugs, and other products. Among these, the oral drugs segment holds a significant position in the compounding pharmacy market, supported by rising demand for personalized medications. Compounded capsules, tablets, lozenges, solutions, and suspensions enable customized dosages, flavors, excipients, and release profiles for pediatric, geriatric, and chronic disease patients. The growing prevalence of endocrine disorders, diabetes, and other chronic conditions further drives demand. Technological advancements in taste masking, sustained-release formulations, and bioavailability enhancement improve patient adherence and treatment outcomes. Increasing emphasis on personalized medicine, compliance with FDA and USP standards, and expanding availability through hospitals, specialty clinics, and retail pharmacies continue to support segment growth.

By therapeutic application, the pain management segment reported the largest market share in 2025.

By therapeutic application, the market is segmented into pain management, hormone replacement therapy, dermal disorders, nutritional supplements, and other therapeutic applications. In 2025, the pain management segment held the largest share of the compounding pharmacy market, driven by the widespread prevalence of acute and chronic pain. Growing cases of arthritis, neuropathic pain, cancer-related pain, migraines, and postoperative conditions are increasing demand for customized analgesic formulations. Compounding pharmacies enable personalized strengths, dosage forms, and delivery methods, supporting improved tolerability and adherence. Advances in topical preparations, transdermal systems, sustained-release formulations, and localized therapies further expand treatment options. Rising demand for individualized pain management, an aging population, and increasing healthcare awareness are expected to support continued segment growth.

Asia Pacific is growing at the highest CAGR in the compounding pharmacy market from 2026 to 2031.

The compounding pharmacy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, Asia Pacific is expected to register the highest CAGR, driven by rising demand for personalized medications, increasing healthcare expenditure, and expanding pharmaceutical and biotechnology industries. Regional growth is further supported by improving healthcare infrastructure, growing awareness of customized therapies, increasing prevalence of chronic diseases, and rising adoption of advanced compounding technologies. Expanding hospital networks, specialty clinics, and compounding pharmacies, along with investments in sterile compounding facilities and quality-control systems, are strengthening the region’s capabilities. Additionally, pharmaceutical and healthcare expansion in China, Japan, South Korea, and India is expected to drive demand for customized drug formulations and compounding services.

The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (70%) and Demand Side (30%)
- By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Companies Profiled in the Report:
- Baxter (US)
- Empower Pharmacy (US)
- B. Braun (Germany)
- Fagron (Netherlands)
- QuVa Pharma (US)
- SCA Pharma (US)
- Nephron Pharmaceuticals (US)
- Leiters Health (US)
- Pharmaxo (UK)
- Icon Group (Australia)
- Roseway Labs (UK)
- ITH Pharma (UK)
- Pencol Compounding Pharmacy (Canada)
- Formula 8 (South Africa)
- Aurora Compounding Pharmacy (Canada)

Research Coverage:
This research report categorizes the compounding pharmacy market by product, compounding type, therapeutic application, sterility, and end user. The report includes detailed information on the main factors affecting growth in the compounding pharmacy market, such as drivers, restraints, challenges, and opportunities. It also features an in-depth analysis of key industry players, offering insights into their business overview, products, solutions, strategies, collaborations, partnerships, and agreements. The report covers recent developments such as new approvals, launches, collaborations, acquisitions, and other updates in the compounding pharmacy market.

Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest estimates of revenue for the entire compounding pharmacy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop appropriate go-to-market strategies. This report enables stakeholders to understand the market's key indicators and provides information on the main market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:
- Analysis of key drivers (persistent drug shortages in North America and Europe, full enforcement of USP standards, safety push for ready-to-administer and standardized doses, continued demand creating supply gap for GLP-1 drugs, and trend toward personalization of doses), restraints (resolution of GLP-1 shortages reduces reliance on compounded alternatives, stricter FDA oversight and insanitary conditions enforcement, and limitations on bulk drug substances), opportunities (expansion of hospital outsourcing into anesthesia, critical care, ophthalmic & chemo-adjuncts and radiopharmaceutical compounding standardization), and challenges (capacity bottlenecks in API, excipient supply, and CCI/testing, and limited quality-system maturity and gaps in stability/BUD evidence generation) influencing the growth of the market.
- Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the compounding pharmacy market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the compounding pharmacy market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the compounding pharmacy market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 31
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 31
1.3.2 INCLUSIONS & EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 32
1.3.4 CURRENCY CONSIDERED 33
1.4 STAKEHOLDERS 33
1.5 SUMMARY OF CHANGES 33

2 EXECUTIVE SUMMARY 34
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 34
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 36
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 37
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 38
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 39

3 PREMIUM INSIGHTS 40
3.1 COMPOUNDING PHARMACY MARKET OVERVIEW 40
3.2 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE & REGION 41
3.3 COMPOUNDING PHARMACY MARKET: GEOGRAPHIC SNAPSHOT 42
3.4 COMPOUNDING PHARMACY MARKET SHARE, BY STERILITY, 2026 VS. 2031 42

4 MARKET OVERVIEW 43
4.1 INTRODUCTION 43
4.2 MARKET DYNAMICS 43
4.2.1 DRIVERS 45
4.2.1.1 Persistent drug shortages in North America and Europe 45
4.2.1.2 Enforcement of USP standards 45
4.2.1.3 Push for ready-to-administer (RTA) and standardized doses 45
4.2.1.4 Continued demand-supply gap for GLP-1 drugs 46
4.2.1.5 Trend towards personalization of doses 46
4.2.2 RESTRAINTS 47
4.2.2.1 Resolution of GLP-1 shortages and reduced reliance on compounded alternatives 47
4.2.2.2 Stricter FDA oversight and intensified enforcement of unsanitary conditions violations 47
4.2.2.3 Limitations on bulk drug substances 47
4.2.3 OPPORTUNITIES 48
4.2.3.1 Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic, and chemo-adjuncts 48
4.2.3.2 Radiopharmaceutical compounding standardization 48
4.2.4 CHALLENGES 49
4.2.4.1 Capacity bottlenecks in API, excipient supply, and critical compounding infrastructure testing 49
4.2.4.2 Limited quality-system maturity and gaps in stability/BUD evidence generation 49
4.3 UNMET NEEDS & WHITE SPACES 49
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 50
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 51

5 INDUSTRY TRENDS 52
5.1 PORTER’S FIVE FORCES ANALYSIS 52
5.1.1 THREAT OF NEW ENTRANTS 53
5.1.2 THREAT OF SUBSTITUTES 53
5.1.3 BARGAINING POWER OF SUPPLIERS 53
5.1.4 BARGAINING POWER OF BUYERS 54
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 54
5.2 MACROECONOMIC OUTLOOK 54
5.2.1 INTRODUCTION 54
5.2.2 GDP TRENDS & FORECAST 55
5.2.3 TRENDS IN GLOBAL COMPOUNDING PHARMACY MARKET 55
5.3 VALUE CHAIN ANALYSIS 56
5.4 ECOSYSTEM ANALYSIS 57
5.4.1 ROLE IN ECOSYSTEM 58
5.5 PRICING ANALYSIS 59
5.5.1 INDICATIVE PRICING ANALYSIS FOR COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2025 60
5.5.2 INDICATIVE PRICING ANALYSIS FOR COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2025 60
5.6 KEY CONFERENCES & EVENTS, 2026–2027 61
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 61
5.8 INVESTMENT & FUNDING SCENARIO 62
5.9 IMPACT OF 2025 US TARIFFS ON COMPOUNDING PHARMACY MARKET 63
5.9.1 INTRODUCTION 63
5.9.2 KEY TARIFF RATES 64
5.9.3 PRICE IMPACT ANALYSIS 65
5.9.4 IMPACT ON COUNTRY/REGION 65
5.9.4.1 US 65
5.9.4.2 Europe 66
5.9.4.3 Asia Pacific 66
5.9.4.4 Rest of the World 67
5.9.5 IMPACT ON END-USE INDUSTRIES 67

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 68
6.1 TECHNOLOGY ANALYSIS 68
6.2 KEY EMERGING TECHNOLOGIES 68
6.2.1 AI-DRIVEN FORMULATION & COMPOUNDING MANAGEMENT 68
6.2.2 AUTOMATED & ROBOTIC COMPOUNDING SYSTEMS 68
6.3 ADJACENT TECHNOLOGIES 69
6.3.1 BARCODE & IMAGE-BASED VERIFICATION TECHNOLOGIES 69
6.3.2 CLOSED-SYSTEM TRANSFER & CONTAINMENT TECHNOLOGIES 69
6.4 COMPLEMENTARY TECHNOLOGIES 69
6.4.1 ELECTRONIC PRESCRIBING & COMPOUNDING WORKFLOW MANAGEMENT 69
6.4.2 CLOUD-BASED PHARMACY MANAGEMENT & DATA ANALYTICS 70
6.5 TECHNOLOGY/PRODUCT ROADMAP 70
6.6 FUTURE APPLICATIONS 70
6.7 IMPACT OF AI/GEN AI ON COMPOUNDING PHARMACY MARKET 71
6.7.1 TOP USE CASES & MARKET POTENTIAL 72
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN COMPOUNDING
PHARMACY MARKET 73
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM & IMPACT ON MARKET PLAYERS 73
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN COMPOUNDING PHARMACY MARKET 74

7 SUSTAINABILITY & REGULATORY LANDSCAPE 75
7.1 REGIONAL REGULATIONS & COMPLIANCE 75
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION 75
7.1.2 INDUSTRY STANDARDS 78
7.2 SUSTAINABILITY INITIATIVES 79
7.3 IMPACT & REGULATORY POLICY INITIATIVES 80
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS 80

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 82
8.1 DECISION-MAKING PROCESS 82
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 83
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
8.2.2 KEY BUYING CRITERIA 84
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 85
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 86
8.5 MARKET PROFITABILITY 86

9 COMPOUNDING PHARMACY MARKET, BY PRODUCT 88
9.1 INTRODUCTION 89
9.2 ORAL DRUGS 89
9.2.1 INCREASING DEMAND FOR PRECISE AND CUSTOMIZABLE ORAL FORMULATIONS IN UNMET PATIENT POPULATIONS TO DRIVE MARKET 89
9.3 TOPICAL DRUGS 92
9.3.1 RISING DEMAND FOR PERSONALIZED TOPICAL TREATMENTS
AND ADVANCED DELIVERY VEHICLES TO FUEL MARKET GROWTH 92
9.4 PARENTERAL DRUGS 95
9.4.1 RISING DEMAND FOR STERILE INJECTABLE THERAPIES AND
SUPPLY-CHAIN DISRUPTIONS TO BOOST MARKET GROWTH 95
9.5 OPHTHALMIC DRUGS 98
9.5.1 RISING CASES OF EYE-RELATED DISORDERS TO ACCELERATE
MARKET GROWTH 98
9.6 NASAL DRUGS 101
9.6.1 ADVANCEMENTS IN NASAL DRUG DELIVERY SYSTEMS AND
FAVORABLE REGULATORY POLICIES TO PROPEL MARKET GROWTH 101
9.7 RECTAL DRUGS 104
9.7.1 PERSONALIZED FORMULATIONS AND REGULATORY SUPPORT
TO DRIVE GROWTH IN RECTAL COMPOUNDING THERAPIES 104
9.8 OTHER PRODUCTS 107

10 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE 111
10.1 INTRODUCTION 112
10.2 PHARMACEUTICAL DOSAGE ALTERATION 112
10.2.1 TAILORED DOSAGE FORMS TO ENHANCE PATIENT ADHERENCE AND CUSTOMIZATION IN COMPOUNDED MEDICATIONS 112
10.3 PHARMACEUTICAL INGREDIENT ALTERATION 115
10.3.1 INCREASED NEED FOR CUSTOMIZED PHARMACEUTICAL INGREDIENTS TO ENHANCE PATIENT-CENTRIC COMPOUNDING SOLUTIONS 115
10.4 CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING 118
10.4.1 PERSISTENT GLOBAL DRUG SHORTAGES AND LIMITATIONS OF LARGE-SCALE PHARMACEUTICAL PRODUCTION TO PROPEL ADOPTION 118

11 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION 122
11.1 INTRODUCTION 123
11.2 PAIN MANAGEMENT 123
11.2.1 NEED FOR PERSONALIZED PAIN RELIEF SOLUTIONS FOR CHRONIC AILMENTS TO SUPPORT MARKET 123
11.3 HORMONE REPLACEMENT THERAPY 126
11.3.1 POPULARITY OF PERSONALIZED HORMONE THERAPIES TO DRIVE STEADY GROWTH IN GLOBAL COMPOUNDING PHARMACY MARKET 126
11.4 DERMAL DISORDERS 129
11.4.1 CUSTOMIZED DERMATOLOGICAL SOLUTIONS TO PROPEL GLOBAL COMPOUNDING PHARMACY MARKET EXPANSION 129
11.5 NUTRITIONAL SUPPLEMENTS 132
11.5.1 PERSONALIZED NUTRACEUTICALS TO OFFER NICHE BUT BETTER GROWTH OPPORTUNITIES IN COMPOUNDING PHARMACIES 132
11.6 OTHER THERAPEUTIC APPLICATIONS 135

12 COMPOUNDING PHARMACY MARKET, BY STERILITY 139
12.1 INTRODUCTION 140
12.2 STERILE 140
12.2.1 RTU/RTA STERILE PREPARATIONS AND OPHTHALMIC PACKS TO DRIVE RAPID GROWTH IN COMPOUNDING PHARMACIES 140
12.3 NON-STERILE 143
12.3.1 503A/MAGISTRAL NON-STERILE PREPARATIONS TO DRIVE GLOBAL VOLUME AND VALUE LEADERSHIP IN COMPOUNDING PHARMACIES 143

13 COMPOUNDING PHARMACY MARKET, BY END USER 147
13.1 INTRODUCTION 148
13.2 ADULTS 148
13.2.1 RISING CHRONIC DISEASE BURDEN AND PERSONALIZED THERAPIES TO AUGMENT ADULT SEGMENT GROWTH 148
13.3 GERIATRIC PATIENTS 151
13.3.1 AGING DEMOGRAPHICS AND DOSE-FORM CUSTOMIZATION
TO PROPEL GERIATRIC SEGMENT GROWTH 151
13.4 PEDIATRIC PATIENTS 154
13.4.1 CUSTOMIZED DOSAGE FORMS AND PEDIATRIC-SPECIFIC NEEDS
TO DRIVE GROWTH 154

14 COMPOUNDING PHARMACY MARKET, BY REGION 158
14.1 INTRODUCTION 159
14.2 NORTH AMERICA 160
14.2.1 US 163
14.2.1.1 US to dominate North American compounding pharmacy market during forecast period 163
14.2.2 CANADA 166
14.2.2.1 Personalized treatments, regulatory reinforcement, and supply-gap filling to fuel global compounding pharmacy growth 166
14.3 EUROPE 169
14.3.1 GERMANY 172
14.3.1.1 Aging demographics, technological advancements, and supportive regulations to drive market 172
14.3.2 UK 175
14.3.2.1 Personalized treatments, chronic disease management, and regulatory support to support market growth 175
14.3.3 FRANCE 178
14.3.3.1 Focus on chronic disease management to fuel growth in French compounding pharmacy market 178
14.3.4 ITALY 181
14.3.4.1 Rising commercial drug development pipeline to spur market growth 181
14.3.5 SPAIN 184
14.3.5.1 Global regulatory advancements and rising R&D activities to drive market 184
14.3.6 REST OF EUROPE 187
14.4 ASIA PACIFIC 189
14.4.1 CHINA 193
14.4.1.1 Low manufacturing cost and high demand for medicines to favor market growth 193
14.4.2 JAPAN 195
14.4.2.1 Increasing prevalence of chronic diseases and growing geriatric population to fuel demand for customized medications 195
14.4.3 INDIA 198
14.4.3.1 Increasing pharma R&D activities to support market growth 198
14.4.4 AUSTRALIA 200
14.4.4.1 Innovation in clinical practice and regulatory support to accelerate compounding pharmacy growth 200
14.4.5 SOUTH KOREA 203
14.4.5.1 Regulatory innovation and automation to fuel South Korean compounding pharmacy market growth 203
14.4.6 REST OF ASIA PACIFIC 206
14.5 LATIN AMERICA 208
14.5.1 BRAZIL 211
14.5.1.1 Growing pharmacy & biologics manufacturing sectors and rising R&D spending to drive market 211
14.5.2 MEXICO 214
14.5.2.1 Regulatory improvements, high cancer rates, and robust pharmaceutical industry to boost market growth 214
14.5.3 REST OF LATIN AMERICA 216
14.6 MIDDLE EAST & AFRICA 219
14.6.1 GCC COUNTRIES 222
14.6.1.1 Rising demand for biologics and increasing prevalence of non-communicable diseases to propel market growth 222
14.6.2 REST OF MIDDLE EAST & AFRICA 225

15 COMPETITIVE LANDSCAPE 229
15.1 INTRODUCTION 229
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 229
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2024−2026 229
15.3 REVENUE ANALYSIS, 2023–2025 231
15.4 MARKET SHARE ANALYSIS, 2025 232
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 234
15.5.1 STARS 234
15.5.2 EMERGING LEADERS 234
15.5.3 PERVASIVE PLAYERS 234
15.5.4 PARTICIPANTS 234
15.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2025 236
15.5.5.1 Company footprint 236
15.5.5.2 Region footprint 237
15.5.5.3 Product footprint 238
15.5.5.4 Therapeutic application footprint 239
15.5.5.5 Sterility footprint 240
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 240
15.6.1 PROGRESSIVE COMPANIES 240
15.6.2 RESPONSIVE COMPANIES 240
15.6.3 DYNAMIC COMPANIES 241
15.6.4 STARTING BLOCKS 241
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 242
15.6.5.1 Detailed list of key startup/SMEs 242
15.6.5.2 Competitive benchmarking of key startups/SMEs 243
15.7 COMPANY VALUATION & FINANCIAL METRICS 244
15.7.1 FINANCIAL METRICS 244
15.7.2 COMPANY VALUATION 244
15.8 BRAND/PRODUCT COMPARISON 245
15.9 COMPETITIVE SCENARIO 246
15.9.1 PRODUCT LAUNCHES 246
15.9.2 DEALS 246
15.9.3 EXPANSIONS 247

16 COMPANY PROFILES 248
16.1 KEY PLAYERS 248
16.1.1 BAXTER 248
16.1.1.1 Business overview 248
16.1.1.2 Products offered 249
16.1.1.3 Recent developments 250
16.1.1.3.1 Product launches 250
16.1.1.3.2 Expansions 250
16.1.1.4 MnM view 250
16.1.1.4.1 Key strengths 250
16.1.1.4.2 Strategic choices 250
16.1.1.4.3 Weaknesses & competitive threats 251
16.1.2 EMPOWER PHARMACY 252
16.1.2.1 Business overview 252
16.1.2.2 Products offered 252
16.1.2.3 Recent developments 253
16.1.2.3.1 Product launches 253
16.1.2.3.2 Expansions 254
16.1.2.4 MnM view 254
16.1.2.4.1 Key strengths 254
16.1.2.4.2 Strategic choices 254
16.1.2.4.3 Weaknesses & competitive threats 254
16.1.3 B. BRAUN SE 255
16.1.3.1 Business overview 255
16.1.3.2 Products offered 256
16.1.3.3 Recent developments 257
16.1.3.3.1 Product launches 257
16.1.3.4 MnM view 257
16.1.3.4.1 Key strengths 257
16.1.3.4.2 Strategic choices 257
16.1.3.4.3 Weaknesses & competitive threats 257
16.1.4 FAGRON 258
16.1.4.1 Business overview 258
16.1.4.2 Products offered 259
16.1.4.3 Recent developments 260
16.1.4.3.1 Deals 260
16.1.4.3.2 Expansions 260
16.1.4.4 MnM view 260
16.1.4.4.1 Key strengths 260
16.1.4.4.2 Strategic choices 260
16.1.4.4.3 Weaknesses & competitive threats 261
16.1.5 QUVA PHARMA, INC. 262
16.1.5.1 Business overview 262
16.1.5.2 Products offered 262
16.1.5.3 Recent developments 263
16.1.5.3.1 Expansions 263
16.1.5.4 MnM view 264
16.1.5.4.1 Key strengths 264
16.1.5.4.2 Strategic choices 264
16.1.5.4.3 Weaknesses & competitive threats 264
16.1.6 SCA PHARMA 265
16.1.6.1 Business overview 265
16.1.6.2 Products offered 265
16.1.6.3 Recent developments 266
16.1.6.3.1 Product launches 266
16.1.6.3.2 Deals 266
16.1.7 NEPHRON PHARMACEUTICALS 267
16.1.7.1 Business overview 267
16.1.7.2 Products offered 267
16.1.7.3 Recent developments 268
16.1.7.3.1 Expansions 268
16.1.8 LEITERS HEALTH 269
16.1.8.1 Business overview 269
16.1.8.2 Products offered 269
16.1.8.3 Recent developments 270
16.1.8.3.1 Product Launches 270
16.1.8.3.2 Expansions 270
16.1.9 ICON GROUP 271
16.1.9.1 Business overview 271
16.1.9.2 Products offered 271
16.1.9.3 Recent developments 272
16.1.9.3.1 Deals 272
16.1.10 ROSEWAY LABS 273
16.1.10.1 Business overview 273
16.1.10.2 Products offered 273
16.1.10.3 Recent developments 274
16.1.10.3.1 Deals 274
16.1.11 ITH PHARMA 275
16.1.11.1 Business overview 275
16.1.11.2 Products offered 275
16.1.11.3 Recent developments 276
16.1.11.3.1 Expansions 276
16.1.12 PENCOL COMPOUNDING PHARMACY 277
16.1.12.1 Business overview 277
16.1.12.2 Products offered 277
16.1.13 FORMUL8 278
16.1.13.1 Business overview 278
16.1.13.2 Products offered 278
16.1.14 AURORA COMPOUNDING PHARMACY 279
16.1.14.1 Business overview 279
16.1.14.2 Products offered 279
16.2 OTHER PLAYERS 280
16.2.1 CUSTOM MED APOTHECARY 280
16.2.2 INSTITUTIONAL PHARMACY SOLUTIONS 281
16.2.3 FUSION APOTHECARY 282
16.2.4 INNOVATION COMPOUNDING PHARMACY 282
16.2.5 RX3 COMPOUNDING PHARMACY 283
16.2.6 DOUGHERTY’S PHARMACY, INC. 284
16.2.7 LORRAINE’S PHARMACY 284
16.2.8 WELLS PHARMA 285
16.2.9 OLYMPIA PHARMACY 286
16.2.10 FRESH THERAPEUTICS 287
16.2.11 MEDIOS AG 288

17 RESEARCH METHODOLOGY 289
17.1 RESEARCH DATA 289
17.1.1 SECONDARY DATA 290
17.1.1.1 Key sources of secondary data 290
17.1.1.2 Key objective of secondary research 290
17.1.2 PRIMARY DATA 291
17.1.2.1 Breakdown of primaries 291
17.1.2.2 Key objectives of primary research 292
17.2 MARKET ESTIMATION METHODOLOGY 292
17.2.1 GLOBAL MARKET ESTIMATION 292
17.2.1.1 Company revenue analysis (bottom-up approach) 292
17.2.1.2 Revenue share analysis 293
17.2.1.3 MnM repository analysis 294
17.2.1.4 Primary interviews 294
17.2.2 INSIGHTS OF PRIMARY EXPERTS 295
17.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 295
17.3 MARKET GROWTH RATE PROJECTIONS 297
17.4 DATA TRIANGULATION 299
17.5 STUDY ASSUMPTIONS 300
17.6 RESEARCH LIMITATIONS 300
17.7 RISK ANALYSIS 301

18 APPENDIX 302
18.1 DISCUSSION GUIDE 302
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 306
18.3 CUSTOMIZATION OPTIONS 308
18.4 RELATED REPORTS 308
18.5 AUTHOR DETAILS 309

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 COMPOUNDING PHARMACY MARKET SEGMENTATION & REGIONAL SCOPE 31.
FIGURE 2 COMPOUNDING PHARMACY MARKET: YEARS CONSIDERED 32.
FIGURE 3 MARKET SCENARIO 35.
FIGURE 4 GLOBAL COMPOUNDING PHARMACY MARKET, 2024–2031 35.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023–2026 36.
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF COMPOUNDING PHARMACY MARKET 37.
FIGURE 7 HIGH-GROWTH SEGMENTS IN COMPOUNDING PHARMACY MARKET, 2026–2031 38.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN COMPOUNDING PHARMACY MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 39.
FIGURE 9 PUSH FOR READY-TO-ADMINISTER (RTA) AND STANDARDIZED DOSES TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 40.
FIGURE 10 PHARMACEUTICAL DOSE ALTERATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025 41.
FIGURE 11 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 42.
FIGURE 12 STERILE SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 42.
FIGURE 13 COMPOUNDING PHARMACY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43.
FIGURE 14 COMPOUNDING PHARMACY MARKET: PORTER’S FIVE FORCES ANALYSIS 52.
FIGURE 15 COMPOUNDING PHARMACY MARKET: VALUE CHAIN ANALYSIS 56.
FIGURE 16 COMPOUNDING PHARMACY MARKET: ECOSYSTEM MAP 58.
FIGURE 17 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN.
COMPOUNDING PHARMACY MARKET 62.
FIGURE 18 INVESTMENT AND NUMBER OF DEALS IN COMPOUNDING PHARMACY MARKET, 2023–2025 (USD MILLION) 62.
FIGURE 19 IMPACT OF AI/GEN AI ON COMPOUNDING PHARMACY MARKET 72.
FIGURE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF KEY COMPOUNDING PHARMACY PRODUCTS 83.
FIGURE 21 KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER 84.
FIGURE 22 NORTH AMERICA: COMPOUNDING PHARMACY MARKET SNAPSHOT 160.
FIGURE 23 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET SNAPSHOT 190.
FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023–2025 (USD MILLION) 231.
FIGURE 25 MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET (2025) 232.
FIGURE 26 COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION.
MATRIX (KEY PLAYERS), 2025 235.
FIGURE 27 COMPOUNDING PHARMACY MARKET: COMPANY FOOTPRINT 236.
FIGURE 28 COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 241.
FIGURE 29 EV/EBITDA OF KEY VENDORS 244.
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK.
BETA OF KEY VENDORS 244.
FIGURE 31 COMPOUNDING PHARMACY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 245.
FIGURE 32 BAXTER: COMPANY SNAPSHOT (2025) 249.
FIGURE 33 B. BRAUN SE: COMPANY SNAPSHOT (2025) 256.
FIGURE 34 FAGRON: COMPANY SNAPSHOT (2025) 259.
FIGURE 35 COMPOUNDING PHARMACY MARKET: RESEARCH DESIGN 289.
FIGURE 36 COMPOUNDING PHARMACY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 291.
FIGURE 37 COMPOUNDING PHARMACY MARKET SIZE ESTIMATION.
(SUPPLY-SIDE ANALYSIS), 2025 292.
FIGURE 38 COMPANY REVENUE ANALYSIS-BASED ESTIMATION:.
BOTTOM-UP APPROACH (2025) 293.
FIGURE 39 ILLUSTRATIVE EXAMPLE OF BAXTER: REVENUE SHARE ANALYSIS, (2025) 293.
FIGURE 40 COMPOUNDING PHARMACY MARKET SIZE VALIDATION FROM PRIMARY SOURCES 295.
FIGURE 41 COMPOUNDING PHARMACY MARKET: TOP-DOWN APPROACH 296.
FIGURE 42 COMPOUNDING PHARMACY MARKET: CAGR PROJECTIONS 297.
FIGURE 43 COMPOUNDING PHARMACY MARKET: DATA TRIANGULATION 299.
TABLE 1 COMPOUNDING PHARMACY MARKET: INCLUSIONS & EXCLUSIONS 32.
TABLE 2 COMPOUNDING PHARMACY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 44.
TABLE 3 COMPOUNDING PHARMACY MARKET: PORTER’S FIVE FORCES 53.
TABLE 4 COMPOUNDING PHARMACY MARKET: ROLE IN ECOSYSTEM 58.
TABLE 5 INDICATIVE PRICING ANALYSIS FOR COMPOUNDING PHARMACY PRODUCTS,.
BY KEY PLAYER, 2025 60.
TABLE 6 INDICATIVE PRICING ANALYSIS FOR COMPOUNDING PHARMACY PRODUCTS,.
BY REGION, 2025 60.
TABLE 7 COMPOUNDING PHARMACY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 61.
TABLE 8 US-ADJUSTED RECIPROCAL TARIFF RATES 64.
TABLE 9 CASE STUDIES OF AI IMPLEMENTATION IN COMPOUNDING PHARMACY MARKET 73.
TABLE 10 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN COMPOUNDING.
PHARMACY MARKET 74.
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 76.
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 76.
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 77.
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT.
AGENCIES, AND OTHER ORGANIZATIONS 78.
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPOUNDING PHARMACY PRODUCTS (%) 83.
TABLE 16 KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER 84.
TABLE 17 COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 89.
TABLE 18 COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION,.
2023–2031 (USD MILLION) 90.
TABLE 19 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 90.
TABLE 20 EUROPE: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2031 (USD MILLION) 91.
TABLE 21 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 91.
TABLE 22 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 92.
TABLE 23 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION, 2023–2031 (USD MILLION) 92.
TABLE 24 COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION,.
2023–2031 (USD MILLION) 93.
TABLE 25 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 93.
TABLE 26 EUROPE: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 94.
TABLE 27 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 94.
TABLE 28 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 95.
TABLE 29 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION, 2023–2031 (USD MILLION) 95.
TABLE 30 COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023–2031 (USD MILLION) 96.
TABLE 31 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2031 (USD MILLION) 96.
TABLE 32 EUROPE: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 97.
TABLE 33 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 97.
TABLE 34 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL.
DRUGS, BY COUNTRY, 2023–2031 (USD MILLION) 98.
TABLE 35 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023–2031 (USD MILLION) 98.
TABLE 36 COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023–2031 (USD MILLION) 99.
TABLE 37 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2031 (USD MILLION) 99.
TABLE 38 EUROPE: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 100.
TABLE 39 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 100.
TABLE 40 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2031 (USD MILLION) 101.
TABLE 41 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023–2031 (USD MILLION) 101.
TABLE 42 COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY REGION,.
2023–2031 (USD MILLION) 102.
TABLE 43 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 102.
TABLE 44 EUROPE: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 103.
TABLE 45 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 103.
TABLE 46 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 104.
TABLE 47 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY REGION, 2023–2031 (USD MILLION) 104.
TABLE 48 COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY REGION,.
2023–2031 (USD MILLION) 105.
TABLE 49 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 105.
TABLE 50 EUROPE: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023–2031 (USD MILLION) 106.
TABLE 51 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 106.
TABLE 52 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS,.
BY COUNTRY, 2023–2031 (USD MILLION) 107.
TABLE 53 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY REGION, 2023–2031 (USD MILLION) 107.
TABLE 54 COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION,.
2023–2031 (USD MILLION) 108.
TABLE 55 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS,.
BY COUNTRY, 2023–2031 (USD MILLION) 108.
TABLE 56 EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS,.
BY COUNTRY, 2023–2031 (USD MILLION) 109.
TABLE 57 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS,.
BY COUNTRY, 2023–2031 (USD MILLION) 109.
TABLE 58 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS,.
BY COUNTRY, 2023–2031 (USD MILLION) 110.
TABLE 59 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2031 (USD MILLION) 110.
TABLE 60 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 112.
TABLE 61 COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023–2031 (USD MILLION) 113.
TABLE 62 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 63 EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 64 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 65 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2031 (USD MILLION) 115.
TABLE 66 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023–2031 (USD MILLION) 115.
TABLE 67 COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2023–2031 (USD MILLION) 116.
TABLE 68 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2031 (USD MILLION) 116.
TABLE 69 EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2031 (USD MILLION) 117.
TABLE 70 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2031 (USD MILLION) 117.
TABLE 71 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2031 (USD MILLION) 118.
TABLE 72 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION,.
2023–2031 (USD MILLION) 118.
TABLE 73 COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION, 2023–2031 (USD MILLION) 119.
TABLE 74 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY,.
2023–2031 (USD MILLION) 119.
TABLE 75 EUROPE: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2031 (USD MILLION) 120.
TABLE 76 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2031 (USD MILLION) 120.
TABLE 77 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY,.
2023–2031 (USD MILLION) 121.
TABLE 78 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION,.
2023–2031 (USD MILLION) 121.
TABLE 79 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION,.
2023–2031 (USD MILLION) 123.
TABLE 80 COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION,.
2023–2031 (USD MILLION) 124.
TABLE 81 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD MILLION) 124.
TABLE 82 EUROPE: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT,.
BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 83 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT,.
BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 84 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT,.
BY COUNTRY, 2023–2031 (USD MILLION) 126.
TABLE 85 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION, 2023–2031 (USD MILLION) 126.
TABLE 86 COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPY,.
BY REGION, 2023–2031 (USD MILLION) 127.
TABLE 87 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 127.
TABLE 88 EUROPE: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 89 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 90 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 91 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023–2031 (USD MILLION) 129.
TABLE 92 COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023–2031 (USD MILLION) 130.
TABLE 93 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 94 EUROPE: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 95 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS,.
BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 96 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 97 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023–2031 (USD MILLION) 132.
TABLE 98 COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS,.
BY REGION, 2023–2031 (USD MILLION) 133.
TABLE 99 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2031 (USD MILLION) 133.
TABLE 100 EUROPE: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 101 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 102 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 103 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2023–2031 (USD MILLION) 135.
TABLE 104 COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS,.
BY REGION, 2023–2031 (USD MILLION) 136.
TABLE 105 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 136.
TABLE 106 EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 107 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 108 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 109 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2031 (USD MILLION) 138.
TABLE 110 COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2031 (USD MILLION) 140.
TABLE 111 STERILE COMPOUNDING PHARMACY MARKET, BY REGION,.
2023–2031 (USD MILLION) 140.
TABLE 112 NORTH AMERICA: STERILE COMPOUNDING PHARMACY MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 141.
TABLE 113 EUROPE: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 141.
TABLE 114 ASIA PACIFIC: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 142.
TABLE 115 LATIN AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 142.
TABLE 116 MIDDLE EAST & AFRICA: STERILE COMPOUNDING PHARMACY MARKET,.
BY REGION, 2023–2031 (USD MILLION) 143.
TABLE 117 NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGION,.
2023–2031 (USD MILLION) 144.
TABLE 118 NORTH AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 144.
TABLE 119 EUROPE: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 145.
TABLE 120 ASIA PACIFIC: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 121 LATIN AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 122 MIDDLE EAST & AFRICA: NON-STERILE COMPOUNDING PHARMACY MARKET,.
BY REGION, 2023–2031 (USD MILLION) 146.
TABLE 123 COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2031 (USD MILLION) 148.
TABLE 124 COMPOUNDING PHARMACY MARKET FOR ADULTS, BY REGION,.
2023–2031 (USD MILLION) 149.
TABLE 125 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR ADULTS,.
BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 126 EUROPE: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY,.
2023–2031 (USD MILLION) 150.
TABLE 127 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 128 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 129 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ADULTS,.
BY REGION, 2023–2031 (USD MILLION) 151.
TABLE 130 COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023–2031 (USD MILLION) 152.
TABLE 131 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 132 EUROPE: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS,.
BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 133 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS,.
BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 134 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2031 (USD MILLION) 154.
TABLE 135 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023–2031 (USD MILLION) 154.
TABLE 136 COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023–2031 (USD MILLION) 155.
TABLE 137 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2031 (USD MILLION) 155.
TABLE 138 EUROPE: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS,.
BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 139 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS,.
BY COUNTRY, 2023–2031 (USD MILLION) 156.
TABLE 140 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2031 (USD MILLION) 157.
TABLE 141 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023–2031 (USD MILLION) 157.
TABLE 142 COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2031 (USD MILLION) 159.
TABLE 143 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 161.
TABLE 144 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 161.
TABLE 145 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2031 (USD MILLION) 162.
TABLE 146 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 162.
TABLE 147 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 163.
TABLE 148 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 163.
TABLE 149 US: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 164.
TABLE 150 US: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 164.
TABLE 151 US: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION,.
2023–2031 (USD MILLION) 165.
TABLE 152 US: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 165.
TABLE 153 US: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 165.
TABLE 154 CANADA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 166.
TABLE 155 CANADA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 167.
TABLE 156 CANADA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 167.
TABLE 157 CANADA: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 168.
TABLE 158 CANADA: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 168.
TABLE 159 EUROPE: COMPOUNDING PHARMACY MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 169.
TABLE 160 EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 170.
TABLE 161 EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 170.
TABLE 162 EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 171.
TABLE 163 EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 171.
TABLE 164 EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 172.
TABLE 165 GERMANY: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 173.
TABLE 166 GERMANY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 173.
TABLE 167 GERMANY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 174.
TABLE 168 GERMANY: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 174.
TABLE 169 GERMANY: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 175.
TABLE 170 UK: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 176.
TABLE 171 UK: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 176.
TABLE 172 UK: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION,.
2023–2031 (USD MILLION) 177.
TABLE 173 UK: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 177.
TABLE 174 UK: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 178.
TABLE 175 FRANCE: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 179.
TABLE 176 FRANCE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 179.
TABLE 177 FRANCE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 180.
TABLE 178 FRANCE: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 180.
TABLE 179 FRANCE: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 181.
TABLE 180 ITALY: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 182.
TABLE 181 ITALY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 182.
TABLE 182 ITALY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 183.
TABLE 183 ITALY: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 183.
TABLE 184 ITALY: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 184.
TABLE 185 SPAIN: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 184.
TABLE 186 SPAIN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 185.
TABLE 187 SPAIN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 185.
TABLE 188 SPAIN: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 186.
TABLE 189 SPAIN: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 186.
TABLE 190 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 187.
TABLE 191 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2031 (USD MILLION) 187.
TABLE 192 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 188.
TABLE 193 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 188.
TABLE 194 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 189.
TABLE 195 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 190.
TABLE 196 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 191.
TABLE 197 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2031 (USD MILLION) 191.
TABLE 198 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 192.
TABLE 199 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 192.
TABLE 200 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 193.
TABLE 201 CHINA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 193.
TABLE 202 CHINA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 193.
TABLE 203 CHINA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 194.
TABLE 204 CHINA: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 195.
TABLE 205 CHINA: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 195.
TABLE 206 JAPAN: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 196.
TABLE 207 JAPAN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 196.
TABLE 208 JAPAN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 197.
TABLE 209 JAPAN: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 197.
TABLE 210 JAPAN: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 198.
TABLE 211 INDIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 198.
TABLE 212 INDIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 199.
TABLE 213 INDIA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 199.
TABLE 214 INDIA: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 200.
TABLE 215 INDIA: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 200.
TABLE 216 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 201.
TABLE 217 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 201.
TABLE 218 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 202.
TABLE 219 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 202.
TABLE 220 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 203.
TABLE 221 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 204.
TABLE 222 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2031 (USD MILLION) 204.
TABLE 223 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 205.
TABLE 224 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 205.
TABLE 225 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 206.
TABLE 226 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 206.
TABLE 227 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2031 (USD MILLION) 207.
TABLE 228 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 207.
TABLE 229 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 208.
TABLE 230 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2031 (USD MILLION) 208.
TABLE 231 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 209.
TABLE 232 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 209.
TABLE 233 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2031 (USD MILLION) 210.
TABLE 234 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 210.
TABLE 235 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 211.
TABLE 236 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 211.
TABLE 237 BRAZIL: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 212.
TABLE 238 BRAZIL: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 212.
TABLE 239 BRAZIL: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 213.
TABLE 240 BRAZIL: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 213.
TABLE 241 BRAZIL: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 213.
TABLE 242 MEXICO: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 214.
TABLE 243 MEXICO: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,.
2023–2031 (USD MILLION) 215.
TABLE 244 MEXICO: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 215.
TABLE 245 MEXICO: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 216.
TABLE 246 MEXICO: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 216.
TABLE 247 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 217.
TABLE 248 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2031 (USD MILLION) 217.
TABLE 249 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 218.
TABLE 250 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2031 (USD MILLION) 218.
TABLE 251 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2031 (USD MILLION) 219.
TABLE 252 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY REGION,.
2023–2031 (USD MILLION) 219.
TABLE 253 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 220.
TABLE 254 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2031 (USD MILLION) 220.
TABLE 255 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 221.
TABLE 256 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2031 (USD MILLION) 221.
TABLE 257 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2031 (USD MILLION) 222.
TABLE 258 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 223.
TABLE 259 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2031 (USD MILLION) 223.
TABLE 260 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 224.
TABLE 261 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY STERILITY,.
2023–2031 (USD MILLION) 224.
TABLE 262 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY END USER,.
2023–2031 (USD MILLION) 225.
TABLE 263 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,.
BY PRODUCT, 2023–2031 (USD MILLION) 226.
TABLE 264 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,.
BY COMPOUNDING TYPE, 2023–2031 (USD MILLION) 226.
TABLE 265 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,.
BY THERAPEUTIC APPLICATION, 2023–2031 (USD MILLION) 227.
TABLE 266 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,.
BY STERILITY, 2023–2031 (USD MILLION) 227.
TABLE 267 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,.
BY END USER, 2023–2031 (USD MILLION) 228.
TABLE 268 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2024−2026 229.
TABLE 269 COMPOUNDING PHARMACY MARKET: DEGREE OF COMPETITION 233.
TABLE 270 COMPOUNDING PHARMACY MARKET: REGION FOOTPRINT 237.
TABLE 271 COMPOUNDING PHARMACY MARKET: PRODUCT FOOTPRINT 238.
TABLE 272 COMPOUNDING PHARMACY MARKET: THERAPEUTIC APPLICATION FOOTPRINT 239.
TABLE 273 COMPOUNDING PHARMACY MARKET: STERILITY FOOTPRINT 240.
TABLE 274 COMPOUNDING PHARMACY MARKET: DETAILED LIST OF.
KEY STARTUP/SME PLAYERS 242.
TABLE 275 COMPOUNDING PHARMACY MARKET: COMPETITIVE BENCHMARKING.
OF KEY STARTUPS/SME PLAYERS, BY PRODUCT, THERAPEUTIC APPLICATION,.
AND REGION, 2025 243.
TABLE 276 COMPOUNDING PHARMACY MARKET: PRODUCT LAUNCHES,.
JANUARY 2023–SEPTEMBER 2026 246.
TABLE 277 COMPOUNDING PHARMACY MARKET: DEALS, JANUARY 2023–SEPTEMBER 2026 246.
TABLE 278 COMPOUNDING PHARMACY MARKET: EXPANSIONS,.
JANUARY 2023–SEPTEMBER 2026 247.
TABLE 279 BAXTER: COMPANY OVERVIEW 248.
TABLE 280 BAXTER: PRODUCTS OFFERED 249.
TABLE 281 BAXTER: PRODUCT LAUNCHES, JANUARY 2023–SEPTEMBER 2026 250.
TABLE 282 BAXTER: EXPANSIONS, JANUARY 2023–SEPTEMBER 2026 250.
TABLE 283 EMPOWER PHARMACY: COMPANY OVERVIEW 252.
TABLE 284 EMPOWER PHARMACY: PRODUCTS OFFERED 252.
TABLE 285 EMPOWER PHARMACY: PRODUCT LAUNCHES, JANUARY 2023–SEPTEMBER 2026 253.
TABLE 286 EMPOWER PHARMACY: EXPANSIONS, JANUARY 2023–SEPTEMBER 2026 254.
TABLE 287 B. BRAUN SE: COMPANY OVERVIEW 255.
TABLE 288 B. BRAUN SE: PRODUCTS OFFERED 256.